See the DrugPatentWatch profile for Kalbitor
What is Kalbitor (ecallantide) and how is it dosed?
Kalbitor (ecallantide) is used to treat acute attacks of hereditary angioedema (HAE) in people age 16 and older. The standard dosing is a single treatment course given by a healthcare professional.
The usual dose is 30 mg total, administered as 10 mg subcutaneously (under the skin) at each of three separate injection sites.
How is the dose given during an acute hereditary angioedema attack?
For each acute HAE attack, Kalbitor is administered as three subcutaneous injections totaling 30 mg. It must be given by a healthcare professional because of the risk of serious allergic reactions, including anaphylaxis.
Can Kalbitor be repeated if symptoms don’t improve?
For an acute attack, clinicians may reassess the patient after treatment and decide whether additional dosing is needed based on the patient’s response and clinical judgment. Specific repeat-dosing instructions are determined by the treating healthcare professional and the prescribing information.
Does Kalbitor dosing differ by age or body weight?
Kalbitor dosing is the same 30 mg per treatment course for the indicated adult/pediatric population in the prescribing guidance. Body weight is not used to calculate the dose in the standard regimen described for acute treatment.
What side effects or risks are most relevant to dosing?
Because Kalbitor can cause hypersensitivity reactions, the patient should be monitored after administration, and it should be available in settings where allergic reactions can be treated. This risk is one reason dosing is done in a clinical setting rather than by patients at home.
Where to find the exact prescribing-dose instructions
For the most precise, step-by-step administration instructions (including how many doses, spacing, monitoring, and any repeat-treatment rules for nonresponse), check the Kalbitor prescribing information provided by your healthcare system or pharmacy.
Sources
- Kalbitor (ecallantide) prescribing information